David G. Silverman

机构：Roche (United Kingdom) · ORCID：0000-0003-1842-5739

发表论文 329 篇 · 总被引 7633 次 · h-index 47

代表论文

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials (2022 · The Lancet · 被引 789)
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials (2022 · The Lancet · 被引 504)
TENAYA and LUCERNE (2024 · Ophthalmology · 被引 221)
Faricimab Treat-and-Extend for Diabetic Macular Edema (2023 · Ophthalmology · 被引 175)
Visual Function Decline Resulting from Geographic Atrophy (2020 · Ophthalmology Retina · 被引 113)
TENAYA and LUCERNE (2021 · Ophthalmology Science · 被引 86)